WO2006005470A3 - Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge) - Google Patents
Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge) Download PDFInfo
- Publication number
- WO2006005470A3 WO2006005470A3 PCT/EP2005/007176 EP2005007176W WO2006005470A3 WO 2006005470 A3 WO2006005470 A3 WO 2006005470A3 EP 2005007176 W EP2005007176 W EP 2005007176W WO 2006005470 A3 WO2006005470 A3 WO 2006005470A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diseases
- mrge
- therapeutics
- diagnostics
- diseases associated
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 101150041973 Mrgpre gene Proteins 0.000 title abstract 3
- 102000018299 Mas-related G protein-coupled receptor E Human genes 0.000 title 1
- 108050007407 Mas-related G protein-coupled receptor E Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- 208000012931 Urologic disease Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 208000014951 hematologic disease Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 210000003205 muscle Anatomy 0.000 abstract 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 2
- 208000014001 urinary system disease Diseases 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a human MrgE which is associated with the cardiovascular diseases, infections, respiratory diseases, gastroenterological diseases, cancer, metabolic diseases, inflammation, hematological diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, respiratory diseases, gastroenterological diseases, cancer, metabolic diseases, inflammation, hematological diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of MrgE as well as pharmaceutical compositions comprising such compounds.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04016641.5 | 2004-07-15 | ||
| EP04016641 | 2004-07-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2006005470A2 WO2006005470A2 (en) | 2006-01-19 |
| WO2006005470A3 true WO2006005470A3 (en) | 2006-07-20 |
Family
ID=35106893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2005/007176 WO2006005470A2 (en) | 2004-07-15 | 2005-07-02 | Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge) |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006005470A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0502497A (en) * | 2005-06-28 | 2007-02-06 | Univ Minas Gerais | use of protein-coupled receptor agonists and antagonists, but as modulators of apoptotic activity for the study, prevention and treatment of diseases |
| GB0819446D0 (en) * | 2008-10-23 | 2008-12-03 | Univ Hull | Treatment of inflammatory disorders |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001048015A2 (en) * | 1999-12-28 | 2001-07-05 | Pharmacia & Upjohn Company | G protein-coupled receptors |
| WO2001062797A2 (en) * | 2000-02-23 | 2001-08-30 | Pharmacia & Upjohn Company | G protein-coupled receptors |
| WO2001083555A2 (en) * | 2000-05-04 | 2001-11-08 | California Institute Of Technology | Pain signaling molecules |
| US20030162252A1 (en) * | 2000-06-30 | 2003-08-28 | Masanori Miwa | Novel g protein-coupled receptor protein and dna thereof |
-
2005
- 2005-07-02 WO PCT/EP2005/007176 patent/WO2006005470A2/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001048015A2 (en) * | 1999-12-28 | 2001-07-05 | Pharmacia & Upjohn Company | G protein-coupled receptors |
| WO2001062797A2 (en) * | 2000-02-23 | 2001-08-30 | Pharmacia & Upjohn Company | G protein-coupled receptors |
| WO2001083555A2 (en) * | 2000-05-04 | 2001-11-08 | California Institute Of Technology | Pain signaling molecules |
| US20030162252A1 (en) * | 2000-06-30 | 2003-08-28 | Masanori Miwa | Novel g protein-coupled receptor protein and dna thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006005470A2 (en) | 2006-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006027147A3 (en) | Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr) | |
| WO2005093092A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44) | |
| WO2005106012A3 (en) | Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1) | |
| WO2006005469A3 (en) | Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr) | |
| WO2006005470A3 (en) | Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge) | |
| WO2005031345A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2) | |
| WO2005076007A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12) | |
| WO2006021343A3 (en) | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a) | |
| WO2005093091A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26) | |
| WO2005113786A3 (en) | Diagnostics and therapeutics for diseases associated with chymase (cma1) | |
| WO2006010514A3 (en) | Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5) | |
| WO2005101001A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor, family c, group 5, member c (gprc5c) | |
| WO2006010515A3 (en) | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 2a receptor (5ht2a) | |
| WO2005119263A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92) | |
| WO2005113788A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6) | |
| WO2005073729A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11) | |
| WO2005114210A8 (en) | Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 3 (grk3) | |
| WO2005101009A3 (en) | Diagnostics and therapeutics for diseases associated with tachykinin receptor 2 (tacr2) | |
| WO2005106486A3 (en) | Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3) | |
| WO2005100997A3 (en) | Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3) | |
| WO2005075983A3 (en) | Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a3 (nr4a3) | |
| WO2006005461A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 27 (gpr27) | |
| WO2006021347A3 (en) | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3c (5-ht3c) | |
| WO2006013015A3 (en) | Diagnostics and therapeutics for diseases associated with marapsin (mpn) | |
| WO2006021345A3 (en) | Diagnostics and therapeutics for diseases associated with adrenergic alpha-1b receptor (adra1b) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase |